Loading viewer...
earnings
Format: PDF earnings
Immunocore presented its 2Q and 1H 2024 financial results and business updates, highlighting progress across oncology, autoimmune, and infectious disease therapeutic areas. The presentation covered KIMMTRAK commercialization growth opportunities, pipeline development, and strategic pillars for advancing immunomodulating medicines.
earnings
63 Pages
Wesfarmers Limited